Scroll Top
Overview
Corporate Summary

Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s lead drug candidate GT-02287 for the treatment of Parkinson’s disease and other neurodegenerative diseases is currently being evaluated in a Phase 1 clinical trial. With its Magellan drug discovery platform, Gain is transforming drug discovery by integrating Al, physics-based methods and supercomputing power to discover novel allosteric binding sites and potential first-in-class drug candidates from on-demand libraries with 50 billion compounds in less than 3 months.

PRESENTATIONS
August 2024

Corporate Presentation

Q3 2024

Investor Factsheet

Press releases
Clear Filters

BETHESDA, Md., Oct. 09, 2024 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and …

Read more

Partnership to investigate Gain’s structurally targeted allosteric regulator candidates (STARs) in cellular models of Gaucher disease and Parkinson’s disease November 30, 2020 09:40 ET | …

Read more

GT-02287 Demonstrates Disease Modifying Capacity in Both GBA1 and Idiopathic Parkinson’s Disease Models GT-02287 Improves Mitochondrial Function and Provides Neuroprotective Effect in GBA1-Parkinson’s Disease Models …

Read more

Events
Clear Filters

Gain Therapeutics recently participated in BTIG’s Virtual Biotechnology Conference 2024. We look forward to our continued collaboration and growing knowledge in the biotechnology industry. This …

Read more

Business and Corporate Update Call with interim-CEO Gene Mack Date: 8:30am ET, July 1, 2024 Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=EnkGqV2d

H.C. Wainwright Fireside Chat with Gene Mack – 5th Annual Neuro Perspectives Virtual Conference Date: June 27, 2024 Webcast: https://journey.ct.events/view/b9a0531d-bb19-4f33-8566-8e2002792bfb